Kornimate/medical-research-clean huggingface dataset:
intra-operative hyperspectral imaging in neurosurgery

Conditions: Neurosurgery; Neurovascular; Neuro-Oncology

Summary: brain surgery operations include brain tumour removal and blood vessel procedures. each year in the uk, approximately 70,500 patients are diagnosed with a brain tumour, 5,000 of whom undergo surgery. approximately 1,000 patients undergo blood vessel brain surgery. brain tumour surgery involves removing as much of the tumour as safely as possible. if all tumour is removed, patients have significantly better outcomes and live longer. however, even with the best hands and the most modern technology currently available, it is often not possible to reliably identify tumour during surgery. moreover, nerves and blood vessels cannot be reliably identified either during surgery. yet, they need to be preserved to avoid brain damage. due to this uncertainty and the need to balance risks, tumour is often left behind. today, close to 30% of brain tumour patients require repeat surgery owing to tumour left behind during their first surgery. further surgeries are more difficult, pose additional patient risks and lead to increased healthcare costs with often poor patient outcomes. newly developed camera systems have the potential to enhance the surgeon's vision to reliably identify tumour and healthy brain structures. hyperspectral imaging (hsi) is one of the most promising of such technologies. its core ability is to provide very detailed and rich information that is invisible to the human eye. hsi has demonstrated the potential to provide crucial, but currently unavailable, information about tumour and critical brain structures during surgery. however, hsi data is very complex and requires advanced computer-processing for its interpretation. in this project, we will use a hsi imaging system to record data in 81 patient undergoing brain including 63 patients with brain tumours and 18 patients suffering from brain vessel abnormalities. using this data we will develop key computer-processing features to enable real-time image interpretation.


Eligibility criteria:
inclusion criteria: * adult patients aged 18 years and over * patients with a diagnosis of a brain tumour (any type), avm or aneurysm who are scheduled for elective surgery * patients able to provide written informed consent exclusion criteria: * patients under 18 years of age * patients who have previously had brain surgery

Keywords: hyperspectral imaging tissue perfusion tissue oxygenation
truerelief efficacy for supraspinatus tendonitis

Conditions: Supraspinatus Tendinitis; Shoulder Pain

Summary: the investigators hypothesize that truerelief will result in improved outcomes for patients with shoulder pain compared to those receiving the sham truerelief treatment. also, it is likely that those with fewer medical comorbidities will experience the greatest improvement.

supraspinatus tendonitis (sst) is a common source of shoulder pain that primary care, sports medicine, and orthopedic surgeons regularly manage. truerelief's fda-cleared device, called truerelief 1250, is a noninvasive technology that provides pain relief through the delivery of high frequency pulsed direct electrical current to the skin surface around the location of the tendonitis via anode and cathode probes. this study will assess if truerelief may be an effective option in treating sst, given the preliminary data surrounding its anti-inflammatory and subsequent analgesic properties. the investigators are proposing the first double-blind, randomized, sham-controlled study of truerelief to determine a more accurate measurement of its efficacy, specifically in patients with sst. the investigators hypothesize that truerelief will result in improved outcomes in this patient population compared to those receiving the sham truerelief treatment.

Eligibility criteria:
inclusion criteria: * those with shoulder pain of recent onset (\<3 months) * those with supraspinatus tendonitis only (see exclusion criteria below) * those whose physical examination meets either criteria below: * positive impingement tests * at least two of: * jobe * modified jobe * hawkins-kennedy * neer * painful arc: * painful arc at 70-120 degrees abduction and/or * painful arc at 70-120 degrees flexion * pain with resisted abduction and/or external rotation * those between the ages of 18 and 65 * those willing and able to sign consent exclusion criteria: * those who have had ipsilateral shoulder surgery involving the supraspinatus muscle * those who have experienced a fracture or avulsion fracture of any element of the shoulder or forequarter area (rib cage, clavicle, or humerus) * those with full-thickness rotator cuff tear * those with a long head of biceps rupture * those with shoulder pathology other than sst (ex: glenohumeral joint (ghj) arthritis, adhesive capsulitis, labral tear). however, acj arthritis can be admitted since this is a very common comorbidity. * those with comorbidities that may confound the outcome, such as: * diabetes (either type i or type ii) * auto-inflammatory diseases * auto-immune diseases * connective tissue disorders (ehlers danlos syndrome) * those with demand type pacemakers * pregnancy
is spontaneous bacterial peritonitis still responding to 3rd generation cephalosporins?

Conditions: Primary Bacterial Peritonitis

Summary: current european and most other international guidelines recommend the use of a third-generation cephalosporin as the first choice, or amoxicillin-clavulanate acid or fluoroquinolones as an alternative choice . these recommendations are based mainly on clinical trials that were very often conducted a decade or more ago, and on the assumption that e. coli would be involved in nearly half of the cases. the microbial etiology of sbp remains relatively constant; however, the antibiotic resistance rate especially for third-generation cephalosporins (including cefotaxime and ceftazidime), ciprofloxacin, and ofloxacin increased dramatically .

spontaneous bacterial peritonitis (sbp), defined as an infection of ascites in the absence of a contiguous source of infection. spontaneous bacterial peritonitis (sbp) is a common and potentially fatal bacterial infection in patients with cirrhosis and ascites, occurring in 10 to 30% of patients, with in-hospital mortality rates ranging from 20 to 30% . it is secondary to impaired humoral and cellular immune responses that result in indirect intestinal bacterial translocation into the ascitic fluid . sbp is also associated with a poor long-term prognosis for patients, as mortality rates can reach 50 to 70% at 1 year . early diagnosis and early optimal treatment of these infections with appropriate antibiotics and the prevention of hepatorenal syndrome with albumin are required . current european and most other international guidelines recommend the use of a third-generation cephalosporin as the first choice, or amoxicillin-clavulanate acid or fluoroquinolones as an alternative choice. these recommendations are based mainly on clinical trials that were very often conducted a decade or more ago, and on the assumption that e. coli would be involved in nearly half of the cases. the microbial etiology of sbp remains relatively constant; however, the antibiotic resistance rate especially for third-generation cephalosporins (including cefotaxime and ceftazidime), ciprofloxacin, and ofloxacin increased dramatically.

Eligibility criteria:
inclusion criteria: * liver cirrhosis with ascites and sbp exclusion criteria: * ascitic fluid with polymicrobial infections
the health of women study

Conditions: Breast Cancer

Summary: the how study is a first-of-its-kind international online study for women and men with and without a history of breast cancer. the investigators will collect information about your health, your job, your diet, and your family history, among other topics that can help us get a better understanding of breast cancer and its potential causes. periodically, the investigators will send you questionnaires about anything and everything. all you have to do is fill them out online. it's that simple. this is a partnership and the investigators need you for the long haul. the more questionnaires you fill out, the more information the investigators will have that can help us have a better understanding of why women get breast cancer.


Eligibility criteria:
inclusion criteria: * men * women * 18 years and older exclusion criteria: * under the age of 18
the bilateral deficit phenomenon, functional and dynamometric assessment in postmenopausal women

Conditions: Postmenopausal Syndrome; Muscle Weakness

Summary: the bilateral deficit phenomenon (bld) is defined as an inability of the neuromuscular system to generate maximal force when two homonymous limb operate simultaneously (bilateral contraction) with respect to the force developed when both limbs acts separately (unilateral contraction). from an applied perspective, movement patterns of bilateral homonymous limb are often developed during activities of day living, e.g. rising from a chair or opening a jar. the bld can be considered an intrinsic property of the human neuromuscular system but could be enough important to constitute a performance-limiting factor for postmenopausal women that involves a degenerative loss of muscular strength. therefore, a specific analysis of this phenomenon and its relation with activities of daily living, such as climbing a step and rising from a chair, is crucial for detecting variables of neuromuscular performance and develop strategies to minimize the loss of strength.

* 20 postmenopausal women unexperience in strength training or resistance training, without musculoskeletal, neurological diseases, and cardiovascular limiting-diseases were recruited. * maximum strength of lower limbs during leg-press exercise was measured for future analysis. * the force-time curves were measured during climbing a step and rising from a chair. * a fragility phenotype test was applied to the subjects to determine frailty phenotype classification, including; weight loss of greater than 10 lbs in the past 12 months, maximal handgrip strength, time to walk 15-ft at usual pace, self-reported leisure time physical activity, and self-reported exhaustion. * the anthropometric measurements were performed by dual energy x-ray absorptiometry.

Eligibility criteria:
inclusion criteria: * postmenopausal women exclusion criteria: * unexperienced in strength training or resistance training. * not musculoskeletal diseases. * not neurological diseases. * not cardiovascular limiting-diseases. * not fragility or pre-fragility phenotype.

Keywords: musculoskeletal physiological phenomena postmenopause muscle strength absorptiometry, photon
safety and efficacy of converting maintenance kidney and liver transplant recipients with abnormal glucose metabolism from tacrolimus to cyclosporine micro-emulsion

Conditions: Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients

Summary: new onset diabetes mellitus (nodm) post- transplantation decreases patient and graft survival. some immunosuppressive agents are associated with a higher incidence of nodm. this study evaluates the safety and efficacy of converting patients with nodm from tacrolimus to cyclosporine micro-emulsion as a primary immunosuppressant for kidney and liver recipients.


Eligibility criteria:
inclusion criteria: * recipients of first or second cadaveric or living donor kidney transplantation or first cadaveric or living donor liver transplantation * receiving tacrolimus as a primary immunosuppressant * currently on any diabetic agent or meets the american diabetes association definition of diabetes mellitus exclusion criteria: * history of treated diabetes mellitus prior to transplantation * less than 2 weeks post-transplantation for kidney and less than 8 weeks for liver * greater than 36 months post-transplantation * onset of diabetes is greater than 12 months prior to time of study entry * has unacceptable or unstable graft function other protocol-defined inclusion/exclusion criteria may apply.

Keywords: diabetes, glucose, tacrolimus, cyclosporine micro-emulsion, liver, kidney, renal
mri-guided laser induced thermal therapy

Conditions: Malignant Glioma

Summary: does mr-guided laser interstitial thermal therapy (mrglitt) prior to chemotherapy and/or radiation give patients a beneficial increase in overall survival? laser induced thermal therapy (litt) is a minimally invasive procedure for destroying tissue through generation of heat.

laser induced thermal therapy (litt) is a procedure for destroying tissue through generation of heat. when used in conjunction with fiberoptic applicators, it offers an excellent means of minimally invasive surgery. as opposed to other thermal techniques like radio-frequency (rf) ablation, or cryo-ablation, litt may be significantly faster and may exhibit sharper boundary of the thermal ablation zone. more importantly, litt is highly compatible with mr imaging and when coupled with mr thermal imaging (mrti) guidance, precise monitoring of the thermal ablation zone in order to avoid eloquent or critical structures is possible. in this study, we propose to evaluate mr-thermal image guided laser interstitial therapy for the treatment of inoperable brain tumors as upfront therapy prior to initiation of chemotherapy and radiation. mr-thermal imaging (mrti) will be used to provide information on thermal dose delivered to the target and be used to control laser delivery to prevent damage to critical structures.

Eligibility criteria:
inclusion criteria: * subjects that have/will undergo mrglitt for inoperable brain tumor. * tumor size \< 3cm in transverse diameter for each planned applicator placement. * tumor size \< 4 cm in largest dimension. * lesion(s) are clearly defined on pre-therapy contrast enhanced mri scans as determined by the treating surgeon. * karnofsky performance scale score \> 70. * ecog performance status of 2 or better. * biopsy proven histologic diagnosis of malignant glioma. exclusion criteria: * patients with co-existing medical conditions with life expectancy \< 1 year. * patients having received pre-ablation chemotherapy and/or radiation to lesion.
elbow arthroscopy data analysis

Conditions: Osteoarthritis Elbow Left; Osteoarthritis Elbow Right; Lateral Epicondylitis, Left Elbow; Lateral Epicondylitis, Right Elbow; Plica Syndromes; Osteochondritis Dissecans

Summary: the purpose of this study is to evaluate preoperative objective measurements and operative objective measurements to determine if there is any effect to postoperative outcomes. patients who were 13 years old or greater at the time of arthroscopic osteocapsular release were followed clinically and radiographically to determine best practice and optimal treatment and technique, risk and rate of complication, and postoperative outcomes.


Eligibility criteria:
inclusion criteria: 1. english speaking 2. \>13 years of age 3. patients treated with elbow arthroscopy for elbow arthritis, radiocapitellar plica, osteochondritis dissecans or lateral epicondylitis. exclusion criteria: 1. non-english speaking 2. \<13 years of age
sensory training in distal radius fractures

Conditions: Distal Radius Fractures

Summary: this randomized controlled trial examines the effectiveness of sensory training in patients undergoing rehabilitation for distal radius fractures. forty-four participants (aged 18-65, with no prior upper extremity injuries) will be randomly assigned to a control group (conventional physiotherapy) or an experimental group (conventional physiotherapy plus sensory training, including desensitization and proprioception exercises). assessments will be conducted at baseline, 4 weeks, and 8 weeks using grip strength, sensory function, fine motor skills, pain level, and functional capacity measures. the study aims to compare the impact of sensory training versus conventional physiotherapy on pain reduction, sensory recovery, grip strength, and functional hand use.

this study aims to investigate the effectiveness of sensory training in patients with distal radius fractures. designed as a randomized controlled trial, the study will include 44 participants aged 18-65 years who have not had a prior upper extremity injury and are in the rehabilitation phase after a fracture. participants will be randomly assigned to either the control group (receiving conventional physiotherapy) or the experimental group (receiving conventional physiotherapy plus sensory training, including desensitization and proprioception exercises). assessments will be conducted before treatment, at 4 weeks, and at 8 weeks. the evaluation tools will include grip strength (hand dynamometer \& pinch meter), sensory function (monofilament test), fine motor skills (nine-hole peg test - nhpt), pain level (numerical pain rating scale - nprs), and functional capacity (dash questionnaire). the aim of this study is to compare the effects of sensory training versus conventional physiotherapy on pain reduction, sensory recovery, grip strength, and functional hand use.

Eligibility criteria:
inclusion criteria: * aged 18-65 years * diagnosed with distal radius fracture * in the rehabilitation phase after fracture healing * no prior upper extremity injuries * no neurological or psychiatric disorders affecting hand function * able to comply with the rehabilitation program exclusion criteria: * any other musculoskeletal injury affecting the upper limb * previous upper extremity surgeries * severe neuropathy or sensory disorders * uncontrolled chronic pain conditions

Keywords: distal radius fractures sensory physiotherapy rehabilitation
a trial to investigate the single dose pharmacokinetics of insulin degludec/liraglutide compared with insulin degludec and liraglutide in healthy chinese subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: the main purpose of the trial is to compare the bioavailability (extent of drug absorption into the circulation) of insulin degludec and liraglutide as part of a combination product insulin degludec/liraglutide compared to the corresponding doses of single, separate injections of insulin degludec and liraglutide. participants will receive all three test substances. the order of trial administration will be allocated by chance. during the trial period, serials of blood samples will be collected from the participants at three dosing periods, in order to determine the concentration of insulin degludec and liraglutide. the total volume of blood taken throughout the whole trial period will be less than 400 ml. participants will be asked to stay on daytime and overnight in the trial sites on some predefined days. for other outpatient days, participants need to attend the trial site as required for drug administration or required assessments.


Eligibility criteria:
inclusion criteria: * male and female chinese subjects, who are considered to be generally healthy, based on assessment of medical history, physical examination, and clinical laboratory data, as judged by the investigator * age between 18 to 45 years (both inclusive) at the time of signing informed consent * body mass index (bmi) between 19.0 and 24.0 kg/sqm (both inclusive) * body weight at least 50.0 kg * fasting plasma glucose less than 6.1 mmol/l (110 mg/dl) exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential not using an adequate contraceptive methods throughout the trial including follow-up period. adequate contraceptive measures are sterilisation, intrauterine device (iud), oral contraceptives or barrier methods * donation of any blood or plasma in the past month or in excess of 400 ml within the 90 days preceding screening or surgery or trauma with more than 400 ml blood loss within the 90 days preceding screening * history or presence of cancer, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrine (incl. diabetes and recurrent hypoglycaemia), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders that might have impact on the trial result, as judged by the investigator * use of any prescription or non-prescription medication, except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (mega-dose vitamin therapy not allowed, dose judged by the investigator) within 2 weeks prior to screening
evaluati̇on of the effects of ri̇bose cross-li̇nked thi̇ck collagen membranes wi̇th connecti̇ve ti̇ssue grafts on soft ti̇ssue and post-operati̇ve pati̇ent comfort i̇n areas wi̇th peri̇-implant soft ti̇ssue defects

Conditions: Peri-implant Mucosa Thickness; Peri-implant Mucosa Width; Peri-Implant Tissues

Summary: aim:methods to increase peri-implant mucosa thickness (pimt) in cases of soft tissue deficiency are important to maintain peri-implant health and aesthetics. the aim of this study was to compare the effect of ribose cross-linked thick collagen membrane (rccm) compared to subepithelial connective tissue graft (ctg) in sites with soft tissue deficiency in the horizontal aspect around the implant. materials and methods:in our study, single implant sites in 20 systemically healthy patients were included. 10 patients were operated simultaneously with the implant operation and 10 patients were operated simultaneously with the implant operation. before the operation, pimt and peri-implant mucosa width (pimw) were measured. visual analog scale (vas) and oral health impact profile-14 (ohip-14) scores were recorded on post operative days 1, 3 and 7. at 1 and 3 months, vas and ohip-14 measurements were repeated. keywords:connective tissue graft, collagen membrane, soft tissue, peri-implant mucosa thickness, peri-implant mucosa width.


Eligibility criteria:
inclusion criteria: * systemically healthy * the edentulous space for which implant treatment is planned to be single tooth size and molar tooth site * those with soft tissue deficiency in the horizontal aspect in the site where implant treatment is planned * age between 18-60 years * does not have a condition that may cause a bleeding disorder * no nausea-vomiting reflex * patients with good oral hygiene exclusion criteria: * patients with systemic disorders (diabetes, hypertension, radiotherapy/ chemotherapy, etc.) * patients who have insufficient horizontal alveolar bone in the site where implant treatment is planned and who may lead to bone dehiscence after implant placement * patients with collagen allergy * those taking any medication that may affect wound healing * those with bleeding disorders * smokers who smoke more than 10 cigarettes a day * poor oral hygiene * those with vomiting-nausea reflex * allergic to anti-inflammatory drugs * patients with pregnancy/breastfeeding status.

Keywords: collagen membranes soft tissue peri-implant mucosa thickness peri-implant mucosa width connective tissue graft